(Q41613250)

English

Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial

scientific article published on 5 December 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 October 2017

Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial (English)

1 reference

Europe PubMed Central

5 October 2017

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

object named as

Stefan Zeuzem

1 reference

Europe PubMed Central

5 October 2017

Sivi Ouwerkerk-Mahadevan

14

object named as

Sivi Ouwerkerk-Mahadevan

0 references

object named as

Ola Weiland

4

0 references

Pietro Andreone

object named as

Pietro Andreone

8

0 references

K. Rajender Reddy

1

object named as

K Rajender Reddy

1 reference

Europe PubMed Central

5 October 2017

5

object named as

Andrzej Horban

1 reference

Europe PubMed Central

5 October 2017

author name string

Fabien Zoulim

3

1 reference

Europe PubMed Central

5 October 2017

Carol Stanciu

6

1 reference

Europe PubMed Central

5 October 2017

Federico Guillermo Villamil

7

1 reference

Europe PubMed Central

5 October 2017

Jacob George

9

1 reference

Europe PubMed Central

5 October 2017

Elisabeth Dammers

10

1 reference

Europe PubMed Central

5 October 2017

Min Fu

11

1 reference

Europe PubMed Central

5 October 2017

Darryl Kurland

12

1 reference

Europe PubMed Central

5 October 2017

Oliver Lenz

13

1 reference

Europe PubMed Central

5 October 2017

Sivi Ouwerkerk-Mahadevan

14

1 reference

Europe PubMed Central

5 October 2017

Thierry Verbinnen

15

1 reference

Europe PubMed Central

5 October 2017

Jane Scott

16

1 reference

Europe PubMed Central

5 October 2017

Wolfgang Jessner

17

1 reference

Europe PubMed Central

5 October 2017

publication date

5 December 2014

1 reference

Europe PubMed Central

5 October 2017

Lancet Infectious Diseases

1 reference

Europe PubMed Central

5 October 2017

15

1 reference

Europe PubMed Central

5 October 2017

1

1 reference

Europe PubMed Central

5 October 2017

27-35

1 reference

Europe PubMed Central

5 October 2017

Boceprevir for previously treated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Telaprevir for previously untreated chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Response-guided telaprevir combination treatment for hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Telaprevir for previously treated chronic HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Telaprevir for retreatment of HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Measurement properties of skindex-16: A brief quality-of-life measure for patients with skin diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The CES-D Scale: A Self-Report Depression Scale for Research in the General Population

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The validity and reproducibility of a work productivity and activity impairment instrument

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

EuroQol--a new facility for the measurement of health-related quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Sofosbuvir for previously untreated chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

HCV direct-acting antiviral agents: the best interferon-free combinations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2971002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1473-3099(14)71002-3

1 reference

Europe PubMed Central

5 October 2017

1 reference

Europe PubMed Central

5 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41613250&oldid=1925077432"